Pharmacokinetics News and Research RSS Feed - Pharmacokinetics News and Research

The term pharmacokinetics is derived from the ancient Greek words “pharmakon” and “kinetikos”, meaning “drug” and “putting in motion” respectively. It is one of the main branches of pharmacology, and refers to the way that the body reacts on and affects a pharmaceutical substance in the body.
Further Reading
New drug shows promise against Huntington's disease

New drug shows promise against Huntington's disease

A drug that would be the first to target the cause of Huntington's disease (HD) is effective and safe when tested in mice and monkeys, according to data released today that will be presented at the American Academy of Neurology's 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016. [More]
Regulus reports net loss of $7.2 million for fourth quarter 2015

Regulus reports net loss of $7.2 million for fourth quarter 2015

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the fourth quarter and full-year ended December 31, 2015 and provided a summary of recent corporate highlights. [More]
AMRI's net revenues increase $126.4M to 46% in fourth quarter 2015

AMRI's net revenues increase $126.4M to 46% in fourth quarter 2015

AMRI today reported financial and operating results for the fourth quarter and full year ended December 31, 2015 and provided an outlook for 2016. [More]
Allergan's sNDA for TEFLARO (ceftaroline fosamil) accepted by FDA

Allergan's sNDA for TEFLARO (ceftaroline fosamil) accepted by FDA

Allergan plc today announced the U.S. Food and Drug Administration has accepted for filing the company's supplemental New Drug Application (sNDA) for TEFLARO (ceftaroline fosamil). [More]
Ambrisentan avoids sildenafil drug interaction in PAH patients

Ambrisentan avoids sildenafil drug interaction in PAH patients

Sildenafil may be better given to pulmonary arterial hypertension patients in combination with ambrisentan than with bosentan, study findings suggest. [More]
Molecular imaging and radiochemistry: the importance of instrumentation. An interview with Professor Björn Wängler

Molecular imaging and radiochemistry: the importance of instrumentation. An interview with Professor Björn Wängler

I’m Björn Wängler, Professor for Molecular Imaging and Radiochemistry at the medical faculty Mannheim of Heidelberg University. I’m a radiopharmaceutical chemist by background and completed my PhD in 2004 at the University of Mainz. [More]
MabVax receives FDA authorization to initiate 89Zr-HuMab-5B1 Phase I trial in pancreatic cancer patients

MabVax receives FDA authorization to initiate 89Zr-HuMab-5B1 Phase I trial in pancreatic cancer patients

MabVax Therapeutics Holdings, Inc., a clinical-stage oncology drug-development company, announces receipt of notice from the U.S. Food and Drug Administration authorizing initiation of a Phase I clinical trial with 89Zr-HuMab-5B1 as a new generation PET scan cancer imaging agent in patients with pancreatic cancer. [More]
AbbVie doses first subject in adalimumab clinical trial using Halozyme's ENHANZE technology

AbbVie doses first subject in adalimumab clinical trial using Halozyme's ENHANZE technology

Halozyme Therapeutics, Inc. today announced that AbbVie has dosed the first subject in a clinical trial evaluating the safety and pharmacokinetics of adalimumab with Halozyme's proprietary ENHANZE technology. [More]
F-star signs agreement with AbbVie to discover, develop bispecific antibodies in immuno-oncology

F-star signs agreement with AbbVie to discover, develop bispecific antibodies in immuno-oncology

F-star today announced that it has entered into a collaboration and license agreement with AbbVie to research and develop bispecific antibodies in immuno-oncology. Financial terms were not disclosed. [More]
E-cigarettes share similar short-term safety profile as Nicorette products

E-cigarettes share similar short-term safety profile as Nicorette products

A new study, published in the Journal of Regulatory Toxicology and Pharmacology, found that e-cigarettes share a similar short-term safety profile as Nicorette products and are comparable in reducing tobacco withdrawal symptoms. [More]
DURECT reports successful completion of DUR-928 Phase 1 study for acute use indications

DURECT reports successful completion of DUR-928 Phase 1 study for acute use indications

DURECT Corporation today announced the successful completion of a Phase 1 clinical trial with an injectable formulation of DUR-928 intended for acute use indications. DUR-928 is an endogenous, small-molecule, new chemical entity (NCE), which may have broad applicability in metabolic diseases such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), and in acute organ injuries such as acute kidney injury (AKI). [More]
HBI-8000 granted orphan drug designation in Japan for treatment of peripheral T-cell lymphoma

HBI-8000 granted orphan drug designation in Japan for treatment of peripheral T-cell lymphoma

HUYA Bioscience International, Founder, CEO & Executive Chair, Dr. Mireille Gillings today announced that the Ministry of Health, Labour and Welfare granted HBI-8000 orphan drug designation in Japan for peripheral T-cell lymphoma (PTCL). [More]
Alexza reports interim results from AZ-002 Phase 2a study in epilepsy patients

Alexza reports interim results from AZ-002 Phase 2a study in epilepsy patients

Alexza Pharmaceuticals, Inc. today announced interim results of its Phase 2a study of AZ-002 (Staccato alprazolam) in epilepsy patients. AZ-002 produced a dose-related decrease in mean Standardized Photosensivity Range (SPR), the primary endpoint in the study. [More]
DS Biopharma reports completion of DS102 Phase I trial for treatment of fatty liver disorders

DS Biopharma reports completion of DS102 Phase I trial for treatment of fatty liver disorders

DS Biopharma, a privately held biopharmaceutical company, today announced the successful completion of a Phase I trial with an oral formulation of the active pharmaceutical ingredient DS102 (15-HEPE) which is being explored for the treatment of fatty liver disorders, such as non-alcoholic steatohepatitis (NASH) and pulmonary disorders, such as idiopathic pulmonary fibrosis (IPF). [More]
Chi-Med announces initiation of Phase III sulfatinib registration trial in patients with NETs in China

Chi-Med announces initiation of Phase III sulfatinib registration trial in patients with NETs in China

Hutchison China MediTech Limited today announces that Hutchison MediPharma Limited, its drug R&D subsidiary, has initiated SANET-ep, a Phase III sulfatinib (HMPL-012) registration trial in China in patients with extra-pancreatic neuroendocrine tumors ("NETs"), which are all non-pancreatic NETs, including, for example, NETs originating in the lymph, lung and across the gastrointestinal tract. [More]
Novel strategies on the way for difficult-to-treat head and neck cancer

Novel strategies on the way for difficult-to-treat head and neck cancer

Novel strategies are on the way for difficult-to-treat and advanced head and neck cancer, the most heterogeneous group of malignancies which are generally associated with poor survival, and encouraging results have been presented at the first ESMO Asia 2015 Congress in Singapore. [More]
ESSA reports net loss of $11.5 million for year ended September 30, 2015

ESSA reports net loss of $11.5 million for year ended September 30, 2015

ESSA Pharma Inc. today reported financial results for the year ended September 30, 2015. Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with International Financial Reporting Standards ("IFRS"). [More]
Tetra begins human Phase 1 safety trials of BPN14770

Tetra begins human Phase 1 safety trials of BPN14770

Tetra Discovery Partners today announced that the company has initiated human Phase 1 safety trials of its lead compound BPN14770, which Tetra is developing as a potential treatment to both improve memory and slow the progression of Alzheimer's disease. [More]
Phase 1 BelCHOP study shows belinostat and CHOP chemo regimen as first-line treatment for PTCL

Phase 1 BelCHOP study shows belinostat and CHOP chemo regimen as first-line treatment for PTCL

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations and a primary focus in Hematology and Oncology, and Onxeo S.A., an innovative company specializing in the development of orphan oncology drugs, today jointly announced the results from their Phase 1 combination trial of belinostat (Beleodaq) with the CHOP (Cyclophosphamide, Hydroxyl-doxorubicin; Vincristine, and Prednisone) chemotherapy regimen as first-line treatment for newly diagnosed peripheral T-cell lymphoma (PTCL). [More]
Research shows significant step toward improving outcomes, reducing treatment burden for SCD patients

Research shows significant step toward improving outcomes, reducing treatment burden for SCD patients

Emerging therapies and promising new insights in the treatment of sickle cell disease represent a significant step toward improving outcomes and reducing the treatment burden for affected children and adults. Studies reporting these advances will be presented today at the 57th American Society of Hematology Annual Meeting and Exposition. [More]